All In Biotech

BLA 125418 · Sanofi Aventis US

Zaltrap

Ziv-Aflibercept · Injection · Vascular Endothelial Growth Factor Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Dec 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Aug 3, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

468

132 Phase 3, 39 recruiting

FAERS reports

1,304

1,220 serious, 207 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 6, 2025.

ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. ZALTRAP, a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. ( 1 )

Mechanism: Ziv-aflibercept acts as a soluble receptor that binds to human VEGF-A (equilibrium dissociation constant K D of 0.5 pM for VEGF-A 165 and 0.36 pM for VEGF-A 121 ), to human VEGF-B (K D of 1.92 pM), and to human PlGF (K D of 39 pM for PlGF-2). By binding to these endogenous ligands, ziv-aflibercept can inhibit the binding and activation of their cognate receptors. This inhibition can result in decreased neovascularization and decreased vascular permeability. In animals, ziv-aflibercept was shown to inhibit the proliferation of endothelial cells, thereby inhibiting the growth of new blood...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 17, 2015 Supplement 33 · Efficacy Letter
  • Aug 3, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelSummary ReviewLabelReview
1 products under this application
  • ZALTRAP · ZIV-AFLIBERCEPT 4MG · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ziv-Aflibercept" as an intervention, any sponsor and status, largest first.

All 468 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea178
  • hypertension137
  • neutropenia105
  • asthenia73
  • vomiting68
  • proteinuria64
  • death61
  • nausea59
  • disease progression49
  • fatigue48
  • stomatitis43
  • abdominal pain42

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201220
2013120
2014114
2015105
2016109
2017115
2018258
2019184
202092
202128
202221
202341
202464
202519
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zaltrap (Ziv-Aflibercept)

2024 spending

$69K

Beneficiaries

n/a

13 claims

Per beneficiary

n/a

$390.72 per unit

View as table
YearSpending
2020$265,301
2021$0
2022$0
2023$0
2024$68,650

Part B: Zaltrap (Ziv-Aflibercept) · HCPCS J9400

2024 spending

$255K

Beneficiaries

25

110 claims

Per beneficiary

$10,183

2024 ASP limit $6.89 per unit

View as table
YearSpending
2020$1,827,500
2021$1,517,400
2022$1,360,531
2023$683,080
2024$254,571

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 36 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.